2 hours ~ Typical clinic visit, including monitoring after dosing.
As early as day 2 ~ When some patients in the TRANSFORM-2 trial first showed clinically meaningful improvement, faster than the 4~6 weeks typical of oral antidepressants.
FDA-approved since 2019 ~ For treatment-resistant depression. Approved in 2020 for major depressive disorder with acute suicidal ideation or behavior.
If you are reading this, your care coordinator or your doctor has probably told you Spravato could be an option for you. You may also be wondering whether it is worth the time, the cost, or the leap.
That hesitation is reasonable. Spravato is a serious treatment with a serious protocol. The two-hour clinic monitoring, the no-driving rule, the schedule of visits over weeks ~ it is fair to want a clearer picture before saying yes to any of it.
This guide will not pretend the inconveniences are nothing. It will not promise you a specific result. What it will do is explain, in plain terms, what Spravato is, what a session actually feels like, who it works for, what it costs, and how it compares to the alternatives.
By the end, you should know whether this is the right next step to discuss with your coordinator. Not whether to start treatment. Just whether to have one more conversation.
Before we go deep, here is the short version.
Spravato at a glance
| What | The short answer |
| What it is | Esketamine, delivered as a nasal spray. The FDA-approved version of a ketamine-based treatment. |
| FDA-approved for | Treatment-resistant depression (2019). Major depressive disorder with acute suicidal ideation or behavior (2020). |
| Typical schedule | Twice weekly for 4 weeks, then weekly for 4 weeks, then every 1~2 weeks as maintenance. |
| Time per visit | About 2 hours total. 5 minutes of dosing, then 2 hours of monitored recovery. |
| Most common side effects | Dissociation, dizziness, nausea, sedation, short-term blood pressure increase. |
| Insurance | Most major commercial plans and Medicare cover it for treatment-resistant depression. |
| Driving | No driving on dosing days. You will need a ride home. |
| Best fit for | Adults with treatment-resistant depression who have tried two or more antidepressants without lasting relief. |
That is the headline. The rest of this guide explains each row in plain English.
Key takeaways
- Spravato is FDA-approved esketamine, given as a nasal spray in a certified clinic. It is regulated, not experimental.
- A session takes about two hours. Most of that is monitored recovery, not dosing.
- Most major insurers cover Spravato for treatment-resistant depression. The manufacturer’s savings program reduces eligible commercial copays to as little as $10 per session.
- The dissociation people fear is usually milder and shorter than they expected, and the clinical team monitors you the whole time.
- If you are not sure whether Spravato fits your situation, the smallest next step is one more conversation with your Psycle coordinator. We can help you confirm insurance, match you with a REMS-certified clinic in-network, and walk you through your specific schedule. Reply to your coordinator to get started.
So, what is Spravato actually?
Spravato is the brand name for esketamine, a prescription nasal spray approved by the FDA in 2019 to treat depression that has not responded to other treatments. In 2020, the FDA also approved it for major depressive disorder with acute suicidal ideation or behavior.
It is administered only in clinics certified under the FDA’s Spravato REMS program. REMS stands for Risk Evaluation and Mitigation Strategy. In plain terms, it is a federal program that says: this medication is safe and effective when given in specific conditions, so it can only be given in those conditions.
That is why you self-administer the nasal spray under nurse supervision, sit in a monitored room for two hours after, and arrange a ride home. Those are not Psycle’s rules. They are the FDA’s.
The mechanism is short to explain, even if the chemistry behind it is not. Most traditional antidepressants act on serotonin and norepinephrine. Esketamine works on a different brain system called the glutamate pathway, by binding to NMDA receptors. That is the system researchers now believe is involved in treatment-resistant depression, which is why a medication that targets it can help people whom SSRIs have not.
This is an established medical treatment, not an experimental one. Hundreds of thousands of doses have been administered in REMS-certified clinics in the United States since approval.
A note on emerging research. Early studies are exploring whether esketamine could benefit other conditions, such as PTSD and substance use disorders. Those uses are not FDA-approved. Today, only people with a formal diagnosis of treatment-resistant depression or major depressive disorder with acute suicidal ideation can receive Spravato.
What makes Spravato different from other ketamine treatments
- FDA-approved. Specifically for treatment-resistant depression. Other ketamine treatments (IV, IM) are prescribed off-label.
- Insurance-covered. Most major commercial plans and Medicare cover it. Off-label ketamine is typically cash-pay.
- Federally regulated. Delivered only in REMS-certified clinics under a standard protocol.
The full Spravato vs ketamine comparison comes later in this guide. The headline is that Spravato is the regulated, insurance-covered, FDA-approved branch of the ketamine family of treatments.
Now, what the actual experience is like.
What a session actually feels like
This is the part most candidates are worried about. So we will walk through it minute by minute, the way you will live it. There are two visits worth distinguishing: the medical evaluation that comes before your first dose, and the dosing sessions themselves.
Before your first session: the medical evaluation
Before you set foot in the dosing room, your provider completes a medical evaluation to confirm Spravato is safe and appropriate for you.
The evaluation typically covers your full psychiatric history, your current medications, any cardiovascular conditions, history of psychosis or substance use, and whether you are currently on an oral antidepressant.
This visit is also your chance to ask the clinician anything you have not yet asked. The contraindications list later in this guide is what gets reviewed here.
The dosing session
You arrive at the clinic and check in. A nurse takes your blood pressure and your vitals. Both will be measured again during the session. If anything is off, the session is rescheduled. This screening is part of how the monitoring keeps you safe.
You move to the dosing room. It looks more like a quiet recliner space than a hospital room. Some clinics offer eye masks. Most allow you to bring headphones and your own music. The lights are usually dim. The environment is intentionally calm.
You self-administer the nasal spray under the nurse’s supervision. Two devices in a single session is typical, with a short pause between them. The dose is fixed by your prescription. The whole dosing itself takes about five minutes.
Then you wait. Within 10 to 20 minutes, you will start to feel the effects.
Most patients describe the experience as floaty, dreamlike, or “time stretching.” Some describe a mild detachment from their body, or the sense that their thoughts are quieter than usual. This is dissociation. It is the intended effect, not a side effect. The peak typically passes within 45 minutes to an hour. The full experience usually settles within the monitoring window.
You remain fully conscious throughout. You know who you are and where you are. The clinical team is in the room or checking on you at regular intervals.
The nurse checks in periodically. Your blood pressure gets measured at intervals. You can ask for help if you feel nauseous or uncomfortable. You will not be left alone.
Around the two-hour mark, the clinical team clears you to leave. Your pre-arranged ride takes you home. You do not drive. You do not return to work. You rest for the rest of the day.
Many patients are surprised, after their first session, that it was less intense than they had braced for. Strange, yes. Scary, less often. The monitored environment is part of why most people get through it more easily than they expected.
The rest of your day, planned in advance
- Your ride is arranged before you arrive.
- Plan a quiet day. No work calls. No big decisions.
- No driving and no operating heavy machinery until the next day.
- Many patients feel tired or a little spaced for a few hours. Most feel fully normal by the next morning.
Knowing what a single session looks like, the next question is what the full course looks like.
The full course of treatment
Spravato is not a one-time treatment. It is a course delivered in two phases, followed by long-term maintenance.
Induction phase. Twice weekly for the first 4 weeks. This is the most intensive stretch. Eight sessions in a month.
Maintenance phase. Weekly for weeks 5 through 8.
Long-term maintenance. Beyond week 8, dosing typically drops to every 1 to 2 weeks, sometimes monthly, based on how you respond.
The honest read on this: Spravato is a long-term treatment, more like an ongoing antidepressant protocol than a short course you complete and finish. Plan around it the way you would plan around a recurring medical commitment, because that is what it is.
What does that look like in practice? In the induction month, you arrange two rides a week, two clinic visits a week, and two quiet afternoons a week. Some patients schedule sessions early in the morning so the rest of the day is theirs to rest. Others schedule them after work so the recovery happens during their evening anyway. There is no single right answer.
A practical note. You are legally not allowed to operate heavy machinery after a session, so if your work involves driving, machinery, or sharp cognitive demand, plan to take dosing days off entirely.
What if I miss a session?
The clinical team adjusts the schedule. Missing one session is not a setback. Missing multiple in a row during induction may affect how well the treatment takes hold.
If something unavoidable comes up, contact your clinic as early as possible. Rescheduling within the same week is usually preferable to a longer gap.
What if I want to stop?
You can stop at any point. There is no physical withdrawal protocol the way there is with some medications.
The decision to stop should be made with your provider, not unilaterally. They can help you taper or transition if needed. Some patients pause and return later. Others move to a different treatment path entirely.
The next question, before any of this becomes concrete, is whether you are a candidate.
Who is and is not a candidate
Spravato is considered for adults with treatment-resistant major depressive disorder or major depressive disorder with acute suicidal ideation or behavior. Your diagnosis must meet DSM-5 criteria and be documented by a licensed psychiatrist or psychologist.
To qualify under most insurance plans, you will also need documented failure of at least two antidepressant trials at adequate doses and durations. Your provider and your Psycle coordinator can help you confirm what your prior treatment history looks like on paper.
There are also conditions that make Spravato a non-starter. The Spravato medication guide lists the contraindications explicitly. The most important to name:
- Blood vessel disease in the brain, chest, abdominal aorta, arms, or legs
- An abnormal connection between veins and arteries (arteriovenous malformation)
- A history of bleeding in the brain
- Allergy to esketamine, ketamine, or any other ingredient in Spravato
Other conditions require careful case-by-case evaluation rather than automatic exclusion. These include:
- Heart or brain conditions such as high blood pressure, chest pain, slow or fast heartbeats, or history of stroke or heart failure
- History of psychotic disorders, including hallucinations or delusions
- Pregnancy or planning to become pregnant during treatment
- Breastfeeding during treatment
- Liver problems
- Active substance use disorder, particularly involving ketamine
Some medications also interact with Spravato in ways that matter. Central nervous system depressants, psychostimulants, and monoamine oxidase inhibitors (MAOIs) get reviewed during your medical evaluation. Your provider decides whether a current medication needs to be tapered or changed before Spravato can start.
You might be a candidate if:
- You have tried two or more antidepressants without lasting relief
- You are an adult diagnosed with major depressive disorder or treatment-resistant depression
- You can commit to twice-weekly clinic visits for the first month
- You can arrange a ride home after each session
- You do not have untreated high blood pressure or a recent cardiovascular event
- You do not have a history of psychotic disorders
- You are not pregnant or breastfeeding
If most of these apply, it is worth a real conversation with your coordinator about whether Spravato fits.
If Spravato is not a match for you
The conversation does not end here. There is a treatment ladder worth knowing about.
Ketamine therapy works through a similar mechanism on the same glutamate pathway. Off-label IV or IM ketamine is more flexible than Spravato in terms of dose, route, and clinic protocol. Some patients who do not fit Spravato’s eligibility criteria do fit a ketamine clinic’s. The trade-off is that ketamine is largely cash-pay rather than insurance-covered.
Because ketamine and Spravato share a mechanism, they also share many of the same contraindications. If a cardiovascular or psychotic history rules out Spravato, it likely rules out ketamine too.
Transcranial magnetic stimulation (TMS) is the other path worth raising with your coordinator. TMS does not involve any medication entering the bloodstream. It uses focused magnetic pulses to stimulate brain regions involved in mood regulation, which means it does not share Spravato’s cardiovascular contraindications. Research supports TMS for treatment-resistant depression.
Ask your coordinator about ketamine therapy and TMS if Spravato does not fit.
For the candidates Spravato does fit, the next question is almost always about safety.
What the side effects and risks actually are
In the TRANSFORM-2 trial published in The American Journal of Psychiatry, dissociation was the most common side effect, reported by 26.1% of patients on Spravato.
Other side effects observed in the trial included:
- Nausea
- Vertigo
- Dysgeusia (a metallic or bitter taste in the mouth)
- Dizziness
- Headache
- Somnolence (excessive drowsiness)
- Blurred vision
- Paresthesia (abnormal skin sensations)
- Anxiety
- Increased blood pressure during dosing
- Insomnia
- Vomiting
- Diarrhea
Most of these resolve within the monitoring window. You leave the clinic feeling tired but functional, not impaired beyond that day.
In TRANSFORM-2, 7% of participants stopped using Spravato because of side effects. No serious adverse events were considered related to treatment in that trial.
The serious risks are rarer, and they are worth naming directly. In SUSTAIN-1 (JAMA Psychiatry), six patients on Spravato experienced serious adverse events during the first four weeks that investigators considered possibly related to the medication. These included disorientation, sedation, one case of a minor stroke, one case of seizures, and one case of suicidal ideation. After the induction phase, no serious side effects in the trial were considered related to Spravato.
The FDA’s boxed warning for Spravato includes the risk of suicidal thoughts and behaviors, particularly in younger adults. That is part of why monitoring is required and why a treatment plan typically pairs Spravato with an oral antidepressant. The clinical team watches for this. You are not tracking it alone.
Long-term safety
SUSTAIN-3, published in Neuropsychopharmacology, followed patients for up to 4.5 years to assess long-term safety. Across that period, researchers did not identify significant long-term adverse effects, and most side effects were temporary.
A note on bladder health, which is a common concern for anyone who has read about chronic recreational ketamine use. In SUSTAIN-3, 13.3% of patients reported urinary tract infections. Researchers noted that this rate was similar to what is seen in people not taking Spravato, so the finding is not specific to the medication.
The chronic bladder and cognitive issues associated with heavy recreational ketamine use have not been observed at therapeutic Spravato dosing schedules. Spravato is a relatively new medication, so researchers continue to study its long-term profile. The current evidence does not flag a unique long-term risk.
Why the two-hour monitoring exists
- Your blood pressure rises during dosing and needs to come back down before you leave.
- The dissociation passes within about an hour. Discharge happens after, not during.
- The clinical team needs to confirm you are clearheaded enough to leave with your ride.
The protocol is what makes Spravato safe to deliver outside a hospital. It is the trade-off that lets the treatment exist in an outpatient clinic at all.
For most candidates, the real decision question is not safety. It is cost.
What it costs and how insurance handles it
As an FDA-approved treatment, Spravato has a clear pathway to insurance coverage. The medication is recognized by major insurers, including Medicare, Medicaid, Aetna, Blue Cross Blue Shield, Cigna Healthcare, and others.
Because Spravato is expensive and indicated for specific conditions, insurers require evidence that treatment is medically necessary. That means prior authorization. Your clinic submits documentation that typically includes:
- Your diagnosis (treatment-resistant depression or major depressive disorder with acute suicidal ideation)
- Records of previous antidepressant trials, including dose and duration
- Confirmation that you have tried at least two antidepressants without sufficient improvement
- Your current treatment plan, including the oral antidepressant Spravato will be paired with
- Confirmation that treatment will take place at a REMS-certified clinic
The paperwork is not trivial. The good news is that your clinic and your Psycle coordinator handle most of it on your behalf.
Spravato withMe: two separate savings programs
Johnson & Johnson runs two distinct programs under the Spravato withMe umbrella. Together, they cover both the medication cost and the in-clinic monitoring cost.
1. The savings program (medication cost). Eligible commercially insured patients pay as little as $10 per session for the Spravato medication itself. Johnson & Johnson covers the rest of your out-of-pocket share, up to an annual maximum benefit.
To qualify, your insurance plan cannot be government-funded (so Medicare, Medicaid, and VA coverage are not eligible for this program), and the plan must leave you with out-of-pocket costs for Spravato.
2. The observation rebate program (monitoring cost). This program reimburses the cost of the two-hour in-clinic monitoring period. Eligibility mirrors the medication savings program.
The observation rebate is not available to residents of Massachusetts, Minnesota, or Rhode Island due to state law.
To use either program, you enroll once, and then after each session you submit a rebate request form with proof of payment for the monitoring portion.
If you are uninsured or your plan does not cover Spravato
Without insurance, Spravato is expensive because you are paying for both the medication and the clinic’s monitoring time. Some clinics offer payment plans, but insurance-backed access should be the first conversation, and Psycle’s coordinators can help you have it.
If coverage is genuinely unavailable, ask your coordinator about other forms of ketamine. Off-label ketamine is usually cash-pay too, but the per-session cost is generally lower than uncovered Spravato.
The insurance picture, in short
- Most major commercial insurers and Medicare cover Spravato for treatment-resistant depression.
- The Spravato withMe savings program brings eligible commercial copays to as little as $10 per session for the medication.
- A separate observation rebate program covers the cost of in-clinic monitoring (not available in MA, MN, or RI).
- Prior authorization is usually required. Your coordinator handles the paperwork.
How your Psycle coordinator helps
Not every Spravato-certified clinic is in-network with every insurance plan. A clinic can be fully REMS-certified but out-of-network for your specific insurer, which significantly changes what you pay.
We help you match with a certified clinic that is also in-network for your plan. We also support the paperwork around prior authorization, the documentation your insurer will request, and the steps that prevent delays in approval.
The next question is how Spravato compares to the other options on the table.
How it compares to the other options
Most candidates considering Spravato have also heard about other ketamine treatments and possibly TMS. The fair comparison is not “which is best,” it is “which fits your situation.”
Spravato vs IV / IM ketamine
| Spravato (esketamine) | IV / IM ketamine | |
| FDA status | Approved for treatment-resistant depression and MDD with acute suicidal ideation | Used off-label for psychiatric purposes |
| Insurance | Most major plans and Medicare cover it | Typically not covered, cash-pay |
| Delivery | Nasal spray, self-administered under supervision | IV infusion (most common), IM injection, or sublingual |
| Dosing | Fixed nasal dose | Often weight-based or titrated to response |
| Experience intensity | Generally milder dissociation | Often more intense, deeper dissociation |
| Monitoring | 2 hours, federally required (REMS) | Varies by clinic, no federal standard |
| Best for | Patients who want an FDA-approved, insurance-covered protocol | Patients exploring off-label options, often when Spravato is not accessible or not the right fit |
An observational study published in The Journal of Clinical Psychiatry compared outcomes in treatment-resistant depression patients receiving either Spravato or IV ketamine. The researchers found no meaningful difference in overall outcomes between the two groups. Patients on IV ketamine generally required fewer sessions to reach remission.
The trade-off is real. Spravato’s fixed dose and milder experience make it more standardized but less flexible. Ketamine clinics can titrate. Spravato cannot. For some patients, that standardization is a feature. For others, it is a limitation. Your provider can help you weigh which matters more in your case.
Spravato vs TMS vs oral antidepressants
| Spravato | TMS | Oral antidepressants | |
| Speed of onset | Within 1 week for responders, sometimes day 2 | 2~6 weeks | 4~8 weeks |
| Time commitment | 2 hrs/visit, 2x/week for 4 weeks, then less | ~20 min/session, 5x/week for 4~6 weeks | Daily pill |
| Side effect profile | Dissociation, sedation, BP increase during dosing | Mild scalp discomfort, rare seizure risk | Varies widely (weight, sexual, GI common) |
| Durability | Requires ongoing maintenance dosing | Effects can last months to years per course | Continuous while taking medication |
| FDA approvals | TRD, MDD with acute suicidal ideation | Depression, anxious depression, OCD, migraines, smoking cessation | MDD and other depressive disorders |
A 2022 meta-analysis comparing Spravato and TMS for treatment-resistant depression found that both treatments produced significant symptom relief in roughly 60-65% of patients who completed a full course. Spravato tends to act faster. TMS tends to produce longer-lasting results without ongoing maintenance.
The cleanest way to think about the choice: TMS is a drug-free option that has worked for many treatment-resistant patients but requires daily sessions for weeks. Oral antidepressants are the first line for most people because they are accessible and inexpensive, but they do not work for everyone. Spravato is the option that pairs faster onset with insurance coverage, at the cost of the time and ride logistics.
None of these is universally better. Each fits a different candidate. The choice is rarely about which is “best” and almost always about which trade-offs you can live with.
The myths and worries worth naming
These are the questions candidates ask once they trust the conversation enough to ask them. Each gets a direct answer below.
| What people fear | What is actually true |
| “Spravato is just ketamine with a different name and a higher price tag.” | Spravato (esketamine) is one of the two molecules that make up ketamine, isolated and FDA-approved as a nasal spray. It binds more selectively to NMDA receptors, the brain protein thought to drive ketamine’s antidepressant effects. The price difference reflects clinical development, REMS infrastructure, and in-clinic monitoring, which off-label ketamine does not carry. |
| “I am going to have a bad trip.” | Some patients do find the dissociation uncomfortable and report feeling anxious or confused during the experience. The effects are generally milder than recreational psychedelics and closely monitored. The clinical team prepares you in advance and supports you throughout. |
| “Spravato is addictive.” | At therapeutic doses in supervised settings, the misuse risk appears low. The REMS program is part of what limits access to the clinical context. Patients with a history of ketamine misuse may be excluded from Spravato. |
| “Will Spravato bring up difficult memories?” | Some patients do report intense emotional content or surfacing memories during dosing, which may relate to esketamine’s effects on NMDA receptors and memory processing. The clinical team supports you through it, and concurrent therapy can help with integration. |
| “If it is so safe, why does it need two hours of monitoring?” | The monitoring is what makes it safe outside a hospital. Your blood pressure rises during dosing. Dissociation needs time to pass. Discharge happens after both clear. |
| “Will I be on Spravato forever?” | Treatment length varies. Some patients stay on maintenance dosing long-term. Others taper gradually. In one 9-month real-world study, 301 patients showed significantly improved depression scores six months after stopping treatment. |
Beyond the worries, candidates also want to know what the actual research says.
What the evidence actually shows
The body of evidence on Spravato is unusually specific for a treatment this new. Here is what the trials actually found.
Treatment-resistant depression
The TRANSFORM-2 trial, published in The American Journal of Psychiatry, compared Spravato plus a new oral antidepressant against placebo plus a new oral antidepressant in adults with treatment-resistant depression. At 28 days, the Spravato group showed significantly greater reduction in depressive symptoms.
69.3% Response rate at 28 days for Spravato patients in TRANSFORM-2. Source: American Journal of Psychiatry, 2019
As early as day 2. When some patients first showed meaningful improvement, compared to 4~8 weeks for SSRIs.
TRANSFORM-3, published in The American Journal of Geriatric Psychiatry, repeated the design in adults aged 65 and older. Spravato again outperformed the antidepressant-plus-placebo arm, though the effect size was smaller than in the younger adult trial.
For relapse prevention, SUSTAIN-1 (JAMA Psychiatry) showed that patients who responded during induction and continued on Spravato during maintenance had approximately 51% lower relapse risk compared to those switched to placebo. A separate phase 3 trial in JAMA Psychiatry reported that responders who continued maintenance treatment over 16 weeks were 70% less likely to relapse than those who continued on antidepressants alone.
Major depressive disorder with suicidal ideation
ASPIRE-2, published in The American Journal of Psychiatry, found that patients receiving Spravato showed significantly greater reduction in suicidal ideation scores within 24 hours of the first dose compared to placebo. The reduction was maintained at day 25. Safety data was consistent with the TRD trials, with dissociation as the most common adverse event and no unexpected serious effects attributed to Spravato.
Real-world outcomes
Clinical trials are tightly controlled. Real-world data is messier and arguably more useful for predicting how a treatment performs in everyday practice.
A 2022 study published in The Journal of Comparative Effectiveness Research followed 171 treatment-resistant depression patients receiving Spravato over a two-year period. Researchers reported significant reductions in depression and anxiety scores from baseline to last available assessment, with no reports of serious adverse effects.
Limits of the current evidence
A few honest caveats worth holding alongside the response data:
- Study populations. Treatment-resistant depression is difficult to study cleanly, since patient histories vary widely and many participants are on other medications.
- Long-term comparative outcomes. Direct long-term head-to-head trials against ketamine, TMS, or continued antidepressant therapy are still limited.
- Definitions of treatment-resistant. Response rates vary across studies based on how “treatment-resistant” was defined and how many prior treatments a patient had tried.
Studies describe averages. Your response is your own.
What integration and follow-up look like
Spravato is primarily a medical treatment. It is delivered alongside an oral antidepressant, which is part of the FDA-approved protocol rather than an add-on. The combination is what was studied in the trials and what most insurance plans reimburse against.
Integration in the Spravato context is not the structured psychotherapy you may have read about with ketamine-assisted therapy. The dosing session itself is not therapy.
That said, the altered state Spravato produces can create a temporary shift in perspective for some patients. Some providers and patients combine Spravato with psychotherapy before and after sessions for that reason. This is not the standard model, and only a limited number of clinics offer it as a coordinated program. Many patients pursue talk therapy separately during their Spravato course.
There are also personal ways to integrate the experience without formal therapy. Patients commonly use:
- Talking with trusted friends or family members about how they felt after sessions
- Journaling about thoughts, emotions, or insights following treatment
- Meditation to notice shifts in mood and thinking
- Creative outlets as a way to process the experience
Your Psycle coordinator can help you find a therapist who works with patients on alternative treatments if you want that kind of support alongside dosing.
Common objections, named and answered
The two-hour monitoring is not workable for me
The monitoring is non-negotiable. It is a federal requirement under the REMS program, not something a clinic can waive.
What is workable is the scheduling. Some clinics offer early morning slots so the rest of your day is still yours. Others offer end-of-day slots so recovery overlaps with your evening anyway.
Your coordinator can help you find a clinic whose hours fit your life before you commit.
I cannot find a ride twice a week for a month
This is one of the most common practical concerns. It is also one of the most solvable.
Rideshare services count. Family, friends, or partners count. Some clinics maintain a list of local transportation options patients have used successfully.
Your coordinator can help you map out the logistics for the induction month before your first session, so the four-week stretch does not become a series of last-minute scrambles.
I do not want to dissociate
That hesitation is reasonable. Dissociation is uncomfortable for some people, even when it is mild.
What helps: the clinical team prepares you for what to expect, the lighting is dim, you can use an eye mask, music helps, and the peak experience is generally under an hour.
Most patients report that the actual experience was less intense than the anticipation. If your specific reaction is harder than expected, the team adjusts.
I have heard ketamine can damage your bladder
The chronic bladder issues associated with heavy recreational ketamine use have not been observed at therapeutic Spravato dosing schedules.
In the SUSTAIN-3 long-term study, urinary tract infection rates among Spravato patients were similar to rates seen in people not taking Spravato.
Recreational use involves much higher doses, much more frequent dosing, and no medical oversight. If you have a history of bladder issues, raise it with your provider during your evaluation.
What if I do not respond after the induction phase?
Not every patient responds, and the protocol accounts for that. After the induction phase, your provider evaluates whether the treatment is working.
If response is partial, your provider may adjust the dose or extend induction. If there is no response, continuing makes less sense, and your provider will discuss alternatives.
This decision is not yours to make alone. It is a clinical assessment, made together.
I cannot afford it even with insurance
This is worth a direct conversation with your coordinator before you rule it out. The Spravato withMe savings program brings the medication cost to as little as $10 per session for eligible commercially insured patients, and the separate observation rebate program covers the monitoring cost.
If your specific plan still leaves significant out-of-pocket cost after both programs, ask your coordinator about ketamine therapy or TMS. They may be a better financial fit for your situation.
The next step is small
If your care coordinator sent you this guide, the next step is one reply. Or one call you already have on the calendar.
You are not committing to treatment by having that conversation. You are confirming what we have not yet confirmed: whether Spravato fits your specific situation, whether your insurance covers it, which REMS-certified clinic in-network would be the right match, and what your individual schedule could look like.
That conversation is where the abstract becomes concrete. Until then, this guide is the map. The conversation is the route.
If you found this page on your own and you do not yet have a Psycle coordinator, the equivalent first step is the matching questionnaire. Someone will follow up to walk you through your options, check your insurance, and help you figure out whether Spravato, ketamine, or another path fits your situation.
You started this guide wondering whether Spravato is worth the time, the cost, and the leap. You now have the framework to answer that question for yourself, with a coordinator who can fill in the specifics for your situation.
Reply to your coordinator to take the next step.
Talk to someone who gets it ~ start with the Psycle match questionnaire.
Frequently asked questions
Is Spravato FDA-approved for depression?
Yes. The FDA approved Spravato in 2019 for treatment-resistant depression in adults who have tried at least two other antidepressants without sufficient relief.
In 2020, the FDA approved it for major depressive disorder with acute suicidal ideation or behavior.
Spravato must be administered in a clinic certified under the FDA’s Spravato REMS program. Your coordinator can help confirm whether you meet the criteria and match you with a certified provider.
How long does Spravato take to work?
Some patients in the TRANSFORM-2 trial showed clinically meaningful improvement as early as day 2 after their first dose. This is meaningfully faster than the 4~8 weeks typical of SSRIs.
Most patients are evaluated for response at 28 days, after the full induction phase of twice-weekly sessions.
Response varies, and durability often depends on continued maintenance dosing under the supervision of your provider.
Does insurance cover Spravato?
Yes. Most major commercial insurance plans and Medicare cover Spravato for treatment-resistant depression after documented failure of two or more antidepressants.
Coverage requires prior authorization, which your clinic and Psycle coordinator handle on your behalf.
The Spravato withMe savings program can also reduce eligible commercial copays to as little as $10 per session for the medication, with a separate observation rebate program covering the in-clinic monitoring cost.
Can I drive after a Spravato session?
No. You cannot drive after a Spravato session, and you cannot operate heavy machinery. A pre-arranged ride is required for every session.
Most clinics will not allow you to begin a session without a confirmed ride home. Plan the rest of the day to be quiet, and avoid making important decisions until the next morning.
Most patients feel fully normal by the next morning and can drive then.
Is Spravato safe long-term?
The SUSTAIN-3 trial, published in Neuropsychopharmacology, followed patients for up to 4.5 years and did not identify significant long-term adverse effects.
The chronic bladder and cognitive issues associated with heavy recreational ketamine use have not been observed at therapeutic Spravato dosing schedules.
As a relatively new medication, Spravato’s long-term profile continues to be studied. The current evidence does not flag a unique long-term risk.
What is the difference between Spravato and ketamine?
Spravato (esketamine) is one of the two molecules that make up ketamine, isolated and FDA-approved as a nasal spray.
Ketamine therapy in clinics typically uses the full ketamine molecule, delivered via IV, IM, intranasal, or sublingual modalities, and is used off-label for psychiatric conditions.
Spravato is more commonly covered by insurance. Ketamine offers more modality and dose flexibility. Both work on the same glutamate pathway in the brain.
What happens if I want to stop Spravato?
You can stop at any time. There is no physical withdrawal protocol at therapeutic doses on a clinical schedule.
Tell your prescriber so they can update your records and help you think through what comes next. They can help you taper or transition to a different treatment if needed.
Some patients pause and return later. Others move to a different treatment path entirely, such as TMS or ketamine, with their coordinator’s help.
We know you’ve seen enough misleading health content to last a lifetime. That is why every Psycle Health article is written by experienced copywriters, fact-checked against peer-reviewed research, and medically reviewed by the licensed professional listed at the top of this page. We cite vetted sources and never overstate treatment outcomes. Our content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about your care.
